多西紫杉醇联合顺铂治疗晚期非小细胞肺癌

目的：探讨多西紫杉醇联合顺铂治疗晚期非小细胞肺癌（Non-Small Cell Lung Cancer,NSCLC）的临床疗效和不良反应。方法：42例晚期NSCLC患者,采用多西紫杉醇75 mg/m^2加入5%葡萄糖注射液500 mL中静脉滴注1 h,第1天;顺铂25 mg/m^2加入0.9%氯化钠注射液500 mL中静脉滴注,第1-3天。21 d为一个周期,至少二个周期评价疗效。结果：42例患者中,完全缓解（CR）2例,部分缓解（PR）19例,无变化（NC）13例,进展（PD）8例;初治组有效率为54.5%,复治组有效率为45.0%,两组比较,差异无统计学意义（P〉0.05）。中位生存期为10.9个月,中位疾病进展时间为4.8个月,1年生存率为40.5%。Ⅲ-Ⅳ度不良反应：白细胞减少为33.3%,脱发为19.0%,口腔黏膜炎为11.9%。结论：多西紫杉醇联合顺铂治疗晚期非小细胞肺癌有较好的疗效,不良反应轻,耐受性好,值得进一步研究。

The Treatment of Patients with Advdnced Non-Small Cell Lung Cancer by Docetaxel Plus Cisplatin

Objective:To compare the efficacy and safety of docetaxel plus cisplatin in the treatments of patients with advanced non-small cell lung cancer.Methods:Forty-two patients with advanced NSCLC diagnosed pathologically were enrolled into the investigation with age from 28 to 73 years and a ECOG PS of 0~2.The patients received docetaxel 75 mg/m2 on day 1,and cisplatin 25 mg/m2 on day 1~3.The chemotherapy was repeated every 21 days.All the patients received at least 2 cycles.Results:Objective response was obtained in 50.0%(21/42) of patients(2 complete and 19 partial response),whereas 13 patients had no change and 8 patients were progressive.Significant difference not existed between the naive patients and retreated patients(54.5 % vs 45.0 %,P>0.05).Median times to tumor progression was 4.9 months.The median survival times was 10.9 months and 1-year survival rate reached 40.5%.The main toxicities included myelosuppression,nausea,vomiting and alopecia.Conclusion:Docetaxel combined with cisplatin is effective in the treatment of advanced NSCLC,with mild to moderate side effects.